Itvisma (intrathecal onasemnogene abeparvovec) for spinal muscular atrophy
Customize your policy alerts
Sign up for all blue cross blue shield - tennessee policy alerts
Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.
Monitor payer policy activity
Covers use of Itvisma for treatment of spinal muscular atrophy (SMA) in specified pediatric and adult populations when approval criteria are met; applies to BlueCross BlueShield of Tennessee members and their providers.
Itvisma is indicated for treatment of SMA in adults and pediatric patients 2 years of age and older with confirmed SMN1 mutation.
Coverage Criteria for Itvisma (intrathecal onasemnogene abeparvovec)
inv-01: Initial therapy - SMA
Covered when ALL of the following are met for treatment of SMA:
FDA-approved indication applies to adults and pediatric patients 2 years and older
Single total dose policy
Specifies later-onset disease inclusion
Copy number requirement
Policy applies to patients aged 2 years and older
Respiratory support exclusion
Pre-treatment serology requirement
Procedural safety criteria
Safety exclusions
Required monitoring
Avoid concurrent disease-modifying therapy
Immunization requirement
Prior gene therapy exclusion
All indications for Itvisma outside of the FDA‑approved indication for treatment of spinal muscular atrophy (SMA) in patients 2 years of age and older with a confirmed SMN1 mutation are considered experimental/investigational and not medically necessary. Requests for coverage for non‑SMA indications will be denied.
Use of Itvisma for any indication other than the FDA‑approved treatment of SMA in adults and pediatric patients 2 years of age and older with confirmed SMN1 mutation is considered not medically necessary. Providers seeking authorization for uses outside this labeled population should not expect coverage and should document that the indication falls within the FDA‑approved SMA population to avoid denial.
Laboratory and Test Requirements
Provider Actions, Prior Authorization, and Documentation
Prior Authorization Required
Prior authorization required. Genetic confirmation of SMA (bi-allelic SMN1 pathogenic variants), documentation of SMN2 copy number, baseline assessments, and other PA requirements must be submitted to initiate review.
- Genetic confirmation of SMA (bi-allelic SMN1 pathogenic variants) required
- SMN2 copy number documentation required (laboratory assay e.g., quantitative PCR or MLPA)
- Baseline assessments: liver function, platelet count, troponin I, creatinine, neurologic evaluation, HFMSE
Discontinue Other SMA Therapies Before Itvisma
If the member is currently receiving nusinersen (Spinraza) or risdiplam (Evrysdi), these therapies must be discontinued prior to administration of Itvisma.
- Discontinue nusinersen (Spinraza) prior to Itvisma administration
- Discontinue risdiplam (Evrysdi) prior to Itvisma administration
Documentation Required for PA Review
Submission of the following documentation is necessary to initiate the prior authorization review: laboratory assay showing SMN2 copy number, genetic testing demonstrating bi-allelic pathogenic SMN1 variants, and supporting medical records documenting baseline assessments.
- Laboratory assay (e.g., quantitative PCR or MLPA) identifying SMN2 copy number
- Genetic testing results confirming bi-allelic pathogenic SMN1 variants (deletions or point mutations)
- Medical records documenting baseline liver function, platelet count, troponin I, creatinine, neurologic evaluation, and Hammersmith Functional Motor Scale-Expanded (HFMSE) assessment
Denial Conditions
Requests will be denied if the indication is not an FDA‑approved SMA age/diagnosis or if approval criteria are not met (including genetic confirmation, age, SMN2 copy number, anti‑AAV9 antibody titer, and other listed requirements).
- Denial if indication is not FDA‑approved for SMA age/diagnosis
- Denial if genetic confirmation (bi-allelic SMN1 pathogenic variants) is not provided
- Denial if SMN2 copy number > 3 when required by criteria
- Denial if anti‑AAV9 antibody titer > 1:50 by ELISA
- Denial if member does not meet age (2 to <18 years for this policy) or other listed clinical/periprocedural criteria
Definitions and Assessment Tools
Background
Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder caused by pathogenic variants in the SMN1 gene. Disease severity is modified by the number of copies of the paralogous SMN2 gene. Intrathecal onasemnogene abeparvovec (Itvisma) is a gene therapy administered intrathecally and is indicated by the FDA for treatment of SMA in adults and pediatric patients 2 years of age and older with confirmed SMN1 mutation. The policy covers Itvisma only when the FDA‑labeled SMA indication and associated authorization criteria are met; other uses are considered investigational and not medically necessary.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.